MolecularMD to Implement Promega’s Microsatellite Instability (MSI) Technology for Immuno-Oncology Applications PORTLAND, Ore. and CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- MolecularMD announces that it has now become a Preferred Provider of Promega’s Microsatellite Instability (MSI) v1.2 Analysis...

MolecularMD Announces Partnership with Indica Labs to Support Improved Clinical Trial Histopathology Workflows Integrating Digital Biomarker Analysis Services PORTLAND, Ore. and CAMBRIDGE, Mass., Sept. 28, 2017 (GLOBE NEWSWIRE) -- MolecularMD, a provider of molecular and tissue-based clinical trial assays and diagnostics for oncology based drug...